Marfan syndrome (MFS) is an autosomal dominant disease caused by mutations in the gene (FBN1) of fibrillin-1, a major determinant of the extracellular matrix (ECM). Functional impairment in the cardiac left ventricle (LV) of these patients is usually a consequence of aortic valve disease. However, LV passive stiffness may also be affected by chronic changes in mechanical load and ECM dysfunction. Passive stiffness is determined by the giant sarcomeric protein titin that has two main cardiac splice isoforms: the shorter and stiffer N2B and the longer and more compliant N2BA. Their ratio is thought to reflect myocardial response to pathologies. Whether this ratio and titin’s sarcomeric layout is altered in MFS is currently unknown. Here, we studied LV samples from MFS patients carrying FBN1 mutation, collected during aortic root replacement surgery. We found that the N2BA:N2B titin ratio was elevated, indicating a shift toward the more compliant isoform. However, there were no alterations in the total titin content compared with healthy humans based on literature data. Additionally, while the gross sarcomeric structure was unaltered, the M-band was more extended in the MFS sarcomere. We propose that the elevated N2BA:N2B titin ratio reflects a general adaptation mechanism to the increased volume overload resulting from the valvular disease and the direct ECM disturbances so as to reduce myocardial passive stiffness and maintain diastolic function in MFS.
Marfan syndrome cardiomyocytes show excess of titin isoform N2BA and extended sarcomeric M-band
D. Kellermayer and C.M. Șulea contributed equally to this paper.
Disclosures: B. Merkely reported personal fees from Boehringer Ingelheim, Daiichi Sankyo, DUKE Clinical Institut, Novartis; grants from Biotronik, Boehringer Ingelheim, DUKE Clinical Institut, Eli Lilly, and Novartis outside the submitted work; and being Rector (academic leader) of Semmelweis University Director and Chair of the Heart and Vascular Center of Semmelweis University, National leader of Librexia Program, National leader of New Amsterdam trial, National leader of DAPA ACT HF-TIMI 68 trial, National leader of MIRACLE trial, National leader of FINEARTS-HF trial, National leader of REALIZE-K trial, National leader of SOS-AMI trial, National leader of DELIVER trial, National leader of GARDEN-TIMI 74 trial, National leader of ENDEAVOR trial, National leader of EMPACT-MI trial, and National leader of CARDINAL-HF trial. No other disclosures were reported.
D. Kellermayer’s current affiliation is Department of Pathology, Faculty of Medicine, University of Pécs, Pécs, Hungary.
This work is part of a special issue on Myofilament Structure and Function.
- Award Id(s): K135076,K135360,FK135462,FK145928
- Award Id(s): BO/00314/24/5,BO/00242/24
- Award Id(s): ÚNKP-19-3-I,ÚNKP-23-3-II-SE-22,TKP2021-EGA,TKP2021-NVA
- Award Id(s): RRF-2.3.1-21-2022-00003
- Award Id(s): RRF-2.3.1-21-2022-00004
- Award Id(s): TKP2021-EGA-23,TKP2021-NVA-15
Dalma Kellermayer, Cristina M. Șulea, Hedvig Tordai, Kálmán Benke, Miklós Pólos, Bence Ágg, Roland Stengl, Máté Csonka, Tamás Radovits, Béla Merkely, Zoltán Szabolcs, Miklós Kellermayer, Balázs Kiss; Marfan syndrome cardiomyocytes show excess of titin isoform N2BA and extended sarcomeric M-band. J Gen Physiol 5 May 2025; 157 (3): e202413690. doi: https://doi.org/10.1085/jgp.202413690
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement